Applications Software Technology Acquires Symatrix to Accelerate Global Expansion in Oracle Cloud Services
20.5.2024 15:00:00 EEST | Business Wire | Press release
Applications Software Technology (AST), a leading digital transformation solutions provider, today announced the signing of a definitive agreement for the acquisition of IT and Oracle services provider Symatrix. The acquisition of Symatrix, a leading IT and Oracle services provider in the UK, is a meaningful step in AST’s global expansion.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240520063933/en/
“The capabilities of Symatrix complement and broaden AST’s core services and allow us to reach new global markets,” said AST CEO Justin Winter. “Working together we will be able to offer enhanced services to our combined customer base. We’ll continue to deliver high-value solutions that provide measurable value and outcomes for our customers at a global scale.”
Symatrix brings an established UK customer base that strengthens AST’s vertical expertise across numerous industries and provides a platform to further expand in emerging sectors. The deep consulting capabilities of Symatrix will also expand AST’s capabilities across Oracle Cloud Applications, including Supply Chain and Human Capital Management.
“AST is a best-in-class enterprise solutions provider that has developed into a premier consultancy for complex Cloud needs across public and commercial industries,” said Chris Brooks, Symatrix CEO. “Joining forces with AST is a natural progression for Symatrix and allows us to service our customers with even greater resources and technical services.”
“AST and Symatrix represent a powerful combination in Oracle Cloud services,” added Charles Phillips -- Managing Partner for Recognize, Chairman of the Board for AST and former President of Oracle. “The complementary end market exposure helps solidify the businesses’ leadership positions across two continents.”
Following the transition, Chris and the leadership team will remain in their roles with a renewed focus on expanding the UK customer base with a new suite of offerings and delivery geographies from AST.
“At AST, we foster a culture of inclusivity and innovation at every level of our organization,” said Winter. “The Symatrix family embodies these values, and our partnership opens a world of exciting possibilities for our customers and employees.”
About Applications Software Technology (AST) LLC
AST is an award-winning, full-service enterprise solution provider, guiding digital transformation for clients in the Government and Commercial Sectors for more than two decades. Clients look to AST for leadership and assistance in transforming their organizations via software solutions, process engineering, and change management. From cloud technology to legacy on-premises applications, AST’s services encompass all aspects of SaaS, PaaS, and IaaS. AST also offers flexible Managed Services, supporting the needs of over 200 customers around the globe. To learn more, visit www.astcorporation.com.
About Symatrix
Symatrix is a United Kingdom based Oracle HCM, ERP and SCM Cloud Consulting, Application Management and Outsourced Payroll provider. Symatrix works with Public Sector and Commercial clients to innovatively help unlock the endless and exciting possibilities of Oracle Cloud.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240520063933/en/
Contact information
Melissa Sider
Phone: (888) AST-0002
Email: msider@astcorporation.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 09:00:00 EEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 07:00:00 EEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
